The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

1. Issuer's Identity

CIK (Filer ID Number)

0001544227

Name of Issuer

Tempest Therapeutics, Inc.

Jurisdiction of Incorporation/Organization

DELAWARE

Year of Incorporation/Organization

☑ Over Five Years Ago
☐ Within Last Five Years (Specify Year)
☐ Yet to Be Formed

Previous Names ☐ None

Millendo Therapeutics, Inc.
OvaScience, Inc.

Entity Type

☑ Corporation
☐ Limited Partnership
☐ Limited Liability Company
☐ General Partnership
☐ Business Trust
☐ Other (Specify)

2. Principal Place of Business and Contact Information

Name of Issuer

Tempest Therapeutics, Inc.

Street Address 1

2000 SIERRA POINT PARKWAY, SUITE 400

Street Address 2

City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
BRISBANE	CALIFORNIA	94005	415-798-8589

3. Related Persons

Last Name	First Name	Middle Name
Angel	Matthew	

Street Address 1: Tempest Therapeutics, Inc.
Street Address 2: 2000 Sierra Point Parkway, Suite 400
City: Brisbane
State/Province/Country: CALIFORNIA
ZIP/PostalCode: 94005

Relationship: ☑ Executive Officer ☑ Director ☐ Promoter

Clarification of Response (if Necessary):

President and Chief Executive Officer

Last Name	First Name	Middle Name
Ames	Constance	

Street Address 1: Tempest Therapeutics, Inc.
Street Address 2: 2000 Sierra Point Parkway, Suite 400
City: Brisbane
State/Province/Country: CALIFORNIA
ZIP/PostalCode: 94005

Relationship: ☑ Executive Officer ☐ Director ☐ Promoter

Clarification of Response (if Necessary):

Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary

Last Name	First Name	Middle Name
Yee	John	David

Street Address 1: Tempest Therapeutics, Inc.
Street Address 2: 2000 Sierra Point Parkway, Suite 400
City: Brisbane
State/Province/Country: CALIFORNIA
ZIP/PostalCode: 94005

☐ ☐ ☐

Relationship: ☐ Executive Officer ☑ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Richey	William	Drake
Street Address 1	**Street Address 2**	
Tempest Therapeutics, Inc.	2000 Sierra Point Parkway, Suite 400	
City	**State/Province/Country**	**ZIP/PostalCode**
Brisbane	CALIFORNIA	94005

Relationship: ☐ Executive Officer ☑ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Freda-Smith	Nancy	
Street Address 1	**Street Address 2**	
Tempest Therapeutics, Inc.	2000 Sierra Point Parkway, Suite 400	
City	**State/Province/Country**	**ZIP/PostalCode**
Brisbane	CALIFORNIA	94005

Relationship: ☐ Executive Officer ☑ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Frederick	John	Wilbert
Street Address 1	**Street Address 2**	
Tempest Therapeutics, Inc.	2000 Sierra Point Parkway, Suite 400	
City	**State/Province/Country**	**ZIP/PostalCode**
Brisbane	CALIFORNIA	94005

Relationship: ☐ Executive Officer ☑ Director ☐ Promoter

Clarification of Response (if Necessary):

---

4. Industry Group

☐ Agriculture

Banking & Financial Services

- ☐ Commercial Banking
- ☐ Insurance
- ☐ Investing
- ☐ Investment Banking
- ☐ Pooled Investment Fund

  Is the issuer registered as an investment company under the Investment Company Act of 1940?

  ☐ Yes ☐ No
- ☐ Other Banking & Financial Services

☐ Business Services

Energy

- ☐ Coal Mining
- ☐ Electric Utilities
- ☐ Energy Conservation
- ☐ Environmental Services
- ☐ Oil & Gas
- ☐ Other Energy

Health Care

- ☑ Biotechnology
- ☐ Health Insurance
- ☐ Hospitals & Physicians
- ☐ Pharmaceuticals
- ☐ Other Health Care

☐ Manufacturing

Real Estate

- ☐ Commercial
- ☐ Construction
- ☐ REITS & Finance
- ☐ Residential
- ☐ Other Real Estate

☐ Retailing

☐ Restaurants

Technology

- ☐ Computers
- ☐ Telecommunications
- ☐ Other Technology

Travel

- ☐ Airlines & Airports
- ☐ Lodging & Conventions
- ☐ Tourism & Travel Services
- ☐ Other Travel

☐ Other

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
☐ No Revenues		☐ No Aggregate Net Asset Value
☐ $1 - $1,000,000		☐ $1 - $5,000,000

☐ $1,000,001 - $5,000,000	☐ $5,000,001 - $25,000,000
☐ $5,000,001 - $25,000,000	☐ $25,000,001 - $50,000,000
☐ $25,000,001 - $100,000,000	☐ $50,000,001 - $100,000,000
☐ Over $100,000,000	☐ Over $100,000,000
☑ Decline to Disclose	☐ Decline to Disclose
☐ Not Applicable	☐ Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

☐ Rule 504(b)(1) (not (i), (ii) or (iii))
☐ Rule 504 (b)(1)(i)
☐ Rule 504 (b)(1)(ii)
☐ Rule 504 (b)(1)(iii)
☑ Rule 506(b)
☐ Rule 506(c)
☐ Securities Act Section 4(a)(5)

☐ Investment Company Act Section 3(c)
☐ Section 3(c)(1)
☐ Section 3(c)(2)
☐ Section 3(c)(3)
☐ Section 3(c)(4)
☐ Section 3(c)(5)
☐ Section 3(c)(6)
☐ Section 3(c)(7)
☐ Section 3(c)(9)
☐ Section 3(c)(10)
☐ Section 3(c)(11)
☐ Section 3(c)(12)
☐ Section 3(c)(13)
☐ Section 3(c)(14)

7. Type of Filing

☑ New Notice Date of First Sale 2026-09-15 ☐ First Sale Yet to Occur
☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? ☑ Yes ☐ No

9. Type(s) of Securities Offered (select all that apply)

☐ Equity
☐ Debt
☑ Option, Warrant or Other Right to Acquire Another Security
☑ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
☐ Pooled Investment Fund Interests
☐ Tenant-in-Common Securities
☐ Mineral Property Securities
☑ Other (describe)

Pre-funded warrants and Series C and Series D Common Stock Purchase Warrants, including underlying shares of common stock.

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☑ No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
H.C. Wainwright & Co., LLC

Recipient CRD Number ☐ None
000000375

(Associated) Broker or Dealer ☑ None
None

(Associated) Broker or Dealer CRD Number ☑ None
None

Street Address 1
430 Park Avenue

Street Address 2
3rd Floor

City
New York

State/Province/Country
NEW YORK

ZIP/Postal Code
10022

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States ☐ All States ☐ Foreign/non-US

NEW YORK

13. Offering and Sales Amounts

Total Offering Amount	$7,500,000 USD	or ☐ Indefinite
Total Amount Sold	$7,500,000 USD	
Total Remaining to be Sold	$0 USD	or ☐ Indefinite

Clarification of Response (if Necessary):

Offering of 3,105,591 pre-funded warrants and accompanying 3,105,591 Series C and 3,105,591 Series D warrants, including the common stock underlying such warrants at combined exercise price of $0.804. Total offering amount excludes PA warrants (Item 15).

14. Investors

☐ Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$225,000 USD	☐ Estimate
Finders' Fees	$0 USD	☐ Estimate

Clarification of Response (if Necessary):

Includes a cash placement fee equal to 7.0% of the gross proceeds of the offering, reimbursement of $50,000 legal fees and warrants, exercisable upon stockholder approval, to purchase 217,391 common stock at an exercise price of $1.0063 per share.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD ☐ Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Tempest Therapeutics, Inc.	/s/ Matthew Angel	Matthew Angel	President and Chief Executive Officer	2026-10-13

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is

the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.